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Abstract
This paper presents the updated Polish Neuroendocrine Tumour Network expert panel recommendations on the management of neu-
roendocrine neoplasms (NENs) of the stomach and duodenum, including gastrinoma. The recommendations discuss the epidemiology, 
pathogenesis, and clinical presentation of these tumours as well as their diagnosis, including biochemical, histopathological, and localisa-
tion diagnoses. The principles of treatment are discussed, including endoscopic, surgical, pharmacological, and radionuclide treatments. 
Finally, there are also recommendations on patient monitoring.
(Endokrynol Pol 2017; 68 (2): 138–153)
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1. Epidemiology and pathogenesis
1.1. Neuroendocrine neoplasms of the stomach
Neuroendocrine neoplasms (NEN) constitute ap-
proximately 1% of all neoplasms of the stomach [1]. 
Between 5.6 and 8.7% of gastrointestinal NENs are 
gastric neuroendocrine neoplasms (g-NENs). However, 
the rate of g-NENs in the overall group of NENs varies, 
depending on the site where the studies are conducted. 
Recently published data from Argentina indicate that 
g-NENs comprise 6.9% of all gastrointestinal NENs [2], 
whereas the rate reported in an earlier Austrian study 
was 5.6% [1]. The percentage of g-NENs in relation to all 
NENs significantly differs between reports. An Austrian 
study gave 23%, a Canadian study gave 5%, and Taiwan 
study gave 7.4%, whereas the SEER programme gave 
6% [3, 4]. The differences indicate the need for mul-
ticentre, prospective studies with long-term analysis 
in order to better describe the epidemiology of these 
neoplasms in Europe. The prevalence is estimated at 
1-2 cases per 1,000,000 people per year, (1.2/1,000,000 
males, 1.8/1,000,000 females). In the years 1981–2000, 
an 8–9-fold increase in the diagnosis of g-NENs was 
observed, due to the continuously extending indica-
tions for endoscopic examinations [5,6].
In the stomach three clinical and pathogenetic types 
of g-NENs are found, with differences in their clinical 
and histopathological pictures, as well as in the diag-
nostics and therapeutic management (Table I).
Pathogenesis
Type 1 and 2 tumours arise from the enterochromaffin-
like (ECL) cells of the gastric mucosa in response to 
chronic, excessive secretion of gastrin. Secondary 
hypergastrinaemia, caused by achlorhydria accompa-
nying chronic atrophic gastritis (CAG), is responsible 
for the development of g-NENs of type 1. Primary 
hypergastrinaemia in Zollinger-Ellison Syndrome 
(ZES), sporadic or associated with multiple endocrine 
neoplasia 1 (MEN-1), is responsible for g-NENs of type 
2. Gastrin and its derivatives stimulate the proliferation, 
migration, and differentiation of ECL cells, which lead 
to their hyperplasia and dysplasia. Hypergastrinaemia 
without the transforming factor(s) does not result in the 
development of g-NENs [5]. In patients with MEN-1, 
the transforming factor may be a menin defect. The 
following are also mentioned in the literature: protein 
inhibiting apoptosis BCL2, protein p53, fibroblast 
growth factor (FGF), transforming growth factor-α 
(TGF-α), and incorrect function of the REGL protein 
(inhibiting proliferation of ECL cells) [7].
Type 1
Gastric neuroendocrine neoplasms of type 1 (70–80% of 
g-NENs) are found in patients with atrophic gastritis. 
They occur in less than 1% of patients, more often in 
women, and are diagnosed mostly between the ages of 
40 and 60 years. The increased availability of endoscopic 
examinations is expected to lower the age of patients 
diagnosed with g-NETs of type 1 [8, 9].
They rarely present clinical signs, and are diagnosed 
during an endoscopic examination performed due to 
dyspeptic symptoms or anaemia, more frequently due 
to macrocytic than iron-deficiency anaemia [10].
They are usually small lesions (< 1–2 cm), 65% of 
them are multiple, and 78% are polyps [6].
70–85% of the tumours belong to the NET G1 group, 
according to the World Health Organisation (WHO) 
2017 classification [10, 11]. They are rarely invasive. 
2–5% of cases are metastatic, and the ability to produce 
metastases increases along with the tumour size [6]. 
They are almost always slowly growing tumours with 
good prognosis — mortality rates have not been described, 
despite the disease advancement (up to 100% of patients 
with 10-year survival rate). They are non-functional: less 
than 1% of patients with g-NETs of type 1 present the 
symptoms of atypical carcinoid syndrome. Blood serum 
gastrin is significantly elevated, as well as gastric pH.
Type 2
This is the rarest (5–6%) form of g-NET. It occurs exclu-
sively in the course of gastrinoma: in 23–29% of patients 
with ZES/MEN-1, and in 1–3% of sporadic lesions 
[5, 9, 12]. Zollinger-Ellison Syndrome is clinically pre-
sent. Neoplasms are usually small (< 1–2 cm) and fre-
quently multiple, often in the form of polyps. They are 
mostly located in the fundus and body of the stomach, 
only occasionally in the gastric cardia. They are classi-
fied as well-differentiated NETs (G1/G2 according to 
WHO 2017), with a good prognosis, regardless of the 
presence of metastases in as many as 30% of patients 
at the time of diagnosis [11, 12]. The mortality rate as-
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sociated with the disease is less than 10% [6]. Blood 
serum gastrin is significantly elevated, whereas gastric 
pH is very low.
Type 3
This type occurs in 14–25% of the cases of g-NENs. 
I t  i s  found more frequently in males  over 
50 years of age. No predisposing factors have been 
identified. Tumours are single, usually large (> 2 cm 
in diameter) polyps, with ulceration on the surface, 
located in the fundus and body of the stomach. They 
are usually G3 tumours, classified as gastric neuroendo-
crine carcinomas (g-NECs according to WHO 2017) [11]. 
50–100% of the lesions are associated with metastases to 
the lymph nodes and liver. Deaths due to g-NEC occur 
in 25–30% of cases, depending on the level of differen-
tiation and the presence of metastases [6]. Blood serum 
gastrin concentrations and gastric pH are normal. 
Recent publications indicate that, based on the 
morphological differentiation and Ki-67 values, G3 
neoplasms can be divided into prognostic groups: well- 
-differentiated NETs G3 and poorly differentiated NECs 
G3 [1, 2, 4, 11]. The division according to the prolifera-
tion index (Ki-67 > 55%) has clinical consequences for 
the response to chemotherapy (ChTx) and prognosis: 
NECs with Ki-67 > 55% demonstrated better response 
to platin-based ChTx, although the median survival 
was four  months shorter than NETs G3 with lower 
proliferation index values (20–55%) [13].
The introduction of a new division is considered, 
as there have been reports of well-differentiated 
g-NETs of different degrees of malignancy (G1-G3), not 
associated with chronic atrophic gastritis. Moreover, 
gastric neoplasms with mixed endocrine and exocrine 
characteristics have also been described [11]. Presently, 
the literature presents 68 such cases, but there are no 
data available on survival [6].
1.2. Neuroendocrine neoplasms of the duodenum
According to American statistics, neuroendocrine 
neoplasms of the duodenum constitute 2–3% of all 
gastrointestinal tumours [2, 5, 14]. 50–70% of them 
are well-differentiated NETs G1 (according to WHO 
2017) [11]. Five types of duodenal neuroendocrine 
tumours (d-NENs) can be distinguished [14]: 
1) gastrinoma (27–58%), 2) non-functional neoplasms 
with positive results of immunohistochemical tests 
for serotonin and calcitonin, 3) somatostatin (SST)- 
-secreting tumours (23–75%), 4) poorly differenti-
ated duodenal carcinomas, and 5) neoplasms of the 
gangliocytic paraganglioma type (rare). Some authors 
exclude from this group tumours located in the 
ampulla of Vater and its area (approximately 20% of 
NENs), whose clinical course rather resembles pan-
creatic neoplasms, and are often associated with von 
Recklinghausen disease (neurofibromatosis type 1, 
NF-1) [14].
Some authors classify neuroendocrine tumours 
located in the ampulla of Vater as neuroendocrine neo-
plasms of the biliary ducts (next to the neuroendocrine 
neoplasms of the gallbladder and extrahepatic biliary 
ducts), and they constitute approximately 60% of these 
tumours. 50–70% of neuroendocrine neoplasms of the 
ampulla of Vater are well-differentiated NENs (G1 and 
G2), unlike neuroendocrine neoplasms of the gallblad-
der, 90–100% of which are neuroendocrine cancers (G3) 
[15, 16].
Less than 10% of patients with NF-1 develop NEN, 
which is almost always a duodenal somatostatinoma, 
mostly without any clinical symptoms. The clas-
sification of somatostatinoma as a separate clinical 
syndrome has been questioned recently because none 
of 46 patients with a histopathologically diagnosed 
somatostatinoma tumour described by Garbrecht et 
al. presented a full set of the symptoms proposed for 
this syndrome [17].
Over 90% of d-NENs are located in the duodenal 
bulb (58%) and descending duodenum (33%). Tumours 
belonging to d-NENs are usually small (> 75% are 
< 2 cm in diameter), limited to the mucosa and submu-
cosa, but at the moment of diagnosis in 40–60% of cases 
regional lymph node metastases are present. Hepatic 
metastases occur in less than 10% of patients. Multiple 
d-NENs suggest MEN-1 [12].
2. Clinical characteristics
2.1. Neuroendocrine neoplasms of the stomach
Type 1 g-NENs are not characterised by a specific 
clinical picture. They are usually diagnosed during 
a gastroscopy performed due to dyspeptic symptoms. 
The course of the disease is usually mild, and after en-
doscopic or surgical treatment it only requires periodic 
endoscopic surveillance. Recurrence is a characteristic 
feature of these tumours — with an average time to 
recurrence of 24 months [10].
In g-NENs of type 2 the symptoms of ZES dominate 
(described for gastrinoma). Examinations described in 
the first section: “Diagnostic and therapeutic guide-
lines for gastro-entero-pancreatic neuroendocrine 
neoplasms” (see p. 79–110) are necessary. 
G-NECs clinically manifest as abdominal pains, 
anaemia, and weight loss. Their course is malignant, 
and they are usually disseminated at the diagnosis [7].
Gastric neuroendocrine neoplasms very rarely 
(< 1%) cause the symptoms of atypical carcinoid 
syndrome (concomitant hepatic metastases). Flushing 
usually lasts longer and is accompanied by lacrimation, 
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often with lowered arterial pressure. Unlike typical 
carcinoid syndrome, excess histamine can cause over-
growth of the facial skin (“leonine facies”) and its bruis-
ing. Endocardial damage may also occur [18].
2.2. Neuroendocrine neoplasms of the duodenum
2.2.1. Gastrinoma
Gastrinomas are neuroendocrine neoplasms located 
in the duodenum (70%), pancreas (25%), and rarely in 
other sites (5%: stomach, liver, ovary, and lung), secret-
ing gastrin and causing clinical ZES. Hypergastrinaemia 
results in hypersecretion of gastric acid, and conse-
quently in peptic ulcer disease and gastroesophageal 
reflux disease with a severe course [19,20].
Gastrinomas are well-differentiated neoplasms NEN 
G1/G2. They are malignant in 60-90% of cases. 
Recently it has been noted that 81% of patients with 
ZES due to duodenal tumour (i.e. 60–95% of all patients 
with ZES) demonstrate a history of long-term alcohol 
abuse (> 50 g/day). Therefore, this may be a significant 
risk factor for ZES [21].
Depending on its location and the presence of MEN-1, 
a gastrinoma demonstrates the following characteristics 
[12, 20, 22, 23]:
Duodenal gastrinomas:
 — 50–88% of gastrinomas in the sporadic form are 
located in the duodenum;
 — 90–100% of gastrinomas in ZES/MEN-1 are located 
in the duodenum;
 — are small (77% < 1 cm); may be multiple;
 — demonstrate local invasiveness;
 — are usually located in the duodenal bulb and de-
scending duodenum;
 — are associated with metastases to the nearest lymph 
nodes; the primary tumour may also occur in 
a peripancreatic lymph node [24];
 — hepatic metastases are rare (5–10%).
Pancreatic gastrinomas:
 — are large (on average 3.8 cm, 6% < 1 cm);
 — can be located in any part of the pancreas;
 — are associated with frequent hepatic metastases 
(25–35%).
Gastrinomas in the course of MEN-1/ZES:
 — 20–30% of patients with ZES are diagnosed with 
MEN1;
 — 70–100% of MEN-1/ZES are situated in the duode-
num, the tumours are almost always multiple;
 — 15% demonstrate an aggressive clinical course;
 — the average age at diagnosis is 32–35 years (for the 
sporadic form: 48–55 years);
 — in 45% of patients, ZES symptoms precede sympto-
matic hypercalcaemia by a few years;
 — in 25% of MEN1/ZES patients, the family history of 
MEN-1 is negative.
 — in sporadic ZES gastrinomas may occur occasionally 
in the liver (< 1%) and liver/biliary ducts [20, 25, 26, 
27], which has recently been demonstrated also for 
patients with MEN-1/ZES [28].
Zollinger-Ellison Syndrome should be suspected in 
patients with ulcer disease with [20]:
 — multiple ulcers of the upper part of the gastrointes-
tinal tract, with unusual location,
 — relapses after treatment,
 — concomitant severe oesophagitis,
 — negative H. pylori test results,
 — complications of the disease (gastrointestinal tract 
perforation, bleeding),
 — diarrhoea,
 — thickening of the gastric folds (present in 92% of 
ZES patients).
The most common symptoms include persistent 
abdominal pain (79–100% of patients), nausea (38%), 
vomiting (24%), diarrhoea (30–75%), which disap-
pears after the use of protein pump inhibitors (PPI), 
a very characteristic feature, body weight loss (12%), 
and gastrointestinal bleeding. There are no differences 
between the clinical symptoms of pancreatic and duo-
denal gastrinoma [20].
Helicobacter pylori infection is less frequent in ZES 
patients (24–48% of patients) compared to peptic ulcer 
disease not caused by excessive gastrin secretion (90% 
of patients). Therefore, negative results of H. pylori tests 
in patients with recurrent peptic ulcer disease, who do 
not receive NSAIDs or acetylsalicylic acid, should be 
suggestive of gastrinoma [29].
The clinical course is aggressive in approximately 
25% of patients with sporadic gastrinoma, and in 
15% of patients with the ZES/MEN-1 form of the 
disease. The following constitute poor prognostic fac-
tors [30]:
 — inadequate control of gastric acid hypersecretion,
 — hepatic metastases,
 — female sex,
 — sporadic form,
 — short time interval between initial symptoms and 
diagnosis,
 — high fasting serum gastrin (FSG),
 — large size (1–3 cm) of the primary tumour,
 — pancreatic location of the primary tumour,
 — ectopic ACTH secretion in the course of gastrinoma,
 — bone metastases,
 — angioinvasion and perineum infiltration in the his-
tological examination.
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2.2.2. Other neuroendocrine neoplasms of the duo-
denum
The clinical symptoms of other duodenal NENs vary: 
abdominal pain (9–64% of patients), bleeding from the 
upper gastrointestinal tract (11–28%), jaundice (7–32%), 
anaemia (11–28%), vomiting (4–8%), and duodenal 
stenosis (1% of patients). Jaundice, bile duct dilata-
tion, vomiting, and diarrhoea often accompany NENs 
located in the proximity of the ampulla of Vater [30]. 
Duodenal neuroendocrine neoplasms very rarely cause 
carcinoid syndrome. In almost all cases the syndrome is 
atypical (described earlier with gastric carcinoids) [19].
Neuroendocrine neoplasms secreting ectopic  
hormones
In the literature there are reports describing d-NENs 
with Cushing’s syndrome (5–15% of patients), with 
acromegaly (ectopic GRH secretion), and symptoms of 
insulinoma, glucagonoma, and polycythaemia vera [31].
2.2.3. Non-functional duodenal neuroendocrine 
neoplasms
Non-functional duodenal neuroendocrine neoplasms 
do not produce any hormone-dependent clinical symp-
toms. However, an immunohistochemical examination 
demonstrates the presence of gastrin, serotonin, calci-
tonin, and somatostatin in the tumour. These neoplasms 
constitute 70–98% of duodenal tumours. They include 
gangliocytic paragangliomas, which are most frequently 
located in the duodenal bulb area. They are usually large 
and benign tumours, invading the muscular layer [32].
3. Diagnostics
3.1. Biochemical diagnostics
3.1.1. Neuroendocrine neoplasms of the stomach
Biochemical diagnostics of type 1 g-NENs includes 
determination of the following parameters:
 — serum chromogranin A (CgA) concentration [33] 
(*evidence level 5),
 — fasting gastrin [18] (*evidence level 5),
 — daily urinary excretion of 5-hydroxyindoleacetic 
acid (5-HIAA) (*evidence level 5),
 — serum serotonin concentration. Determination should 
be performed only in patients with atypical (rarely 
with typical) carcinoid syndrome (*evidence level 5),
 — vitamin B12 concentration in patients with hyper-
gastrinaemia (*evidence level 3).
Determination of β-hCG, human chorionic gon-
adotropin (presence in the granules of tumour cells, 
possible ectopic secretion), may be useful for the dia-
gnosis [33].
In biochemical diagnostics of type 2 g-NENs
To confirm ZES, the following tests should be per-
formed:
 — determination of fasting serum gastrin (*evidence 
level 3);
 — assessment of serum gastrin concentration after 
stimulation, i.e. the test with secretin (2 units/kg 
bw IV) or calcium gluconate in uncertain cases 
(*evidence level 3);
 — assessment of serum gastrin concentration in pa-
tients after surgery due to gastrinoma, 3–12 months 
after the surgery, then follow-up tests every 6–12 
months for 3–4 years (*evidence level 5);
 — determination of serum CgA concentration (*evi-
dence level 5); 
 — in uncertain cases concerning differentiation of the 
causes of secondary hypergastrinaemia — determi-
nation of gastric pH (pH < 2) [34] (*evidence level 4);
 — in the case of suspected MEN-1 syndrome, screening 
tests described in section 1: “Diagnostic and thera-
peutic guidelines for gastro-entero-pancreatic neu-
roendocrine neoplasms” should be performed (see 
p. 79–110). Concomitant MEN-1 syndrome requires 
confirmation in genetic tests [12] (*evidence level 4).
Diagnostics of ZES
ZES diagnosis requires the evidence of hypergastri-
naemia under fasting conditions, with hypersecretion 
of hydrochloric acid, or low gastric pH (pH < 2). In 
practice, the diagnostics starts with determination of 
serum gastrin concentration under fasting conditions 
(FSG), which is increased to 98% for ZES patients. The 
evidence of hypergastrinaemia is not sufficient to diag-
nose ZES because there are other reasons for increased 
gastrin concentration than gastrinoma [5, 8]:
 — with hypo/achlorhydria — atrophic gastritis, using 
PPI,
 — with hyperchlorhydria: H. pylori infection, pyloric 
stenosis, renal failure, antral G-cell syndromes, short 
bowel syndrome.
In 40–60% of patients with ZES, the FSG value is 
lower than 10 times the normal gastrin concentration 
under fasting conditions, and it is comparable to gastrin 
concentrations in the course of H. pylori infection.
Therefore, the effective eradication of H. pylori is neces-
sary before a gastrinoma diagnosis can be established [8].
Proton pump inhibitors and histamine H2-receptor 
antagonists increase gastrin and CgA concentrations in 
the blood, so previous discontinuation of PPI 10–14 days 
before the planned determination of blood gastrin con-
centration is recommended. In patients with suspected 
gastrinoma, PPI can be substituted in this period with 
oral H2-receptor antagonists, but it is recommended 
*evidence level according to OCEMB [87]
143
Endokrynologia Polska 2017; 68 (2)
SZ
K
O
LE
N
IE
 
PO
D
YP
LO
M
O
W
E
that they are also discontinued at least 48 hours before 
the examination [8]. Because sudden discontinuation of 
PPI in a ZES patient may result in complications due to 
a sudden increase in hydrochloric acid secretion, some 
experts currently recommend conducting diagnostics 
without the withdrawal of PPI, or with a dose reduc-
tion. Unfortunately, diagnosis is then very difficult, and 
using the secretin test is impossible due to the risk of 
a false-positive result. In ambiguous cases, the patients 
should be referred to a specialist centre, and if this is 
not possible a careful attempt to discontinue PPI should 
be made (in patients without symptoms or active ulcer 
disease), and an H2 blocker should be introduced.
Gastrinoma can be diagnosed if the fasting gastrin levels 
are over 10 times the upper limit of normal, and gastric pH 
< 2. In most cases, increased gastrin level is accompanied 
by an increased serum CgA concentration. The blood for 
gastrin determination should be drawn under fasting con-
ditions. If gastrin concentration under fasting conditions is 
increased by less than a factor of 10 times, and the gastric 
pH is ≤ 2, the secretin stimulation test should be performed. 
The test is performed under fasting conditions, and secre-
tin is administered intravenously, at a dose of 2.0 units/kg 
bw. Gastrin is determined at proper intervals, expressed 
in minutes relative to the moment of secretin administra-
tion: –15, –1, +2, +5, +10, +15 , +20, and +30 minutes. 
Gastrinoma diagnosis is confirmed by an increase in gastrin 
concentration by more than 120 pg/ml, at any point dur-
ing the test, in relation to the baseline value. For this value 
of increase in gastrin concentration, the sensitivity of the 
secretin stimulation test is 94% and the specificity is 100%. 
Increasing the value of the diagnostic gastrin increment to 
200 pg/ml reduces the test sensitivity to 82% [8].
The gastrin stimulation test with intravenous 
calcium gluconate is less sensitive, less specific, and 
associated with more adverse reactions. It is rarely 
performed, only if conducting the secretin stimulation 
test is impossible or if its result is negative, while the 
clinical suspicion of gastrinoma is strong [18].
Determination of gastrin concentration on consecu-
tive days demonstrates the referential values in less than 
0.5% of patients with ZES. Gastric pH above 3, on the 
other hand, is a strong indicator excluding the presence 
of gastrinoma. Because in 20–25% of cases gastrinoma is 
an element in MEN-1 syndrome, every patient with ZES 
should undergo the screening tests for MEN1 described 
in section 1: “Diagnostic and therapeutic guidelines for 
gastro-entero-pancreatic neuroendocrine neoplasms” 
(see p. 79–110).
In a small proportion of patients with clinical symp-
toms of ZES resulting from excessive secretion of gastric 
acid, fasting gastrin concentration is normal, and the 
secreting test is negative. In such cases, plasma chol-
ecystokinin (CCK) concentration should be determined 
because the cause could be a CCK-secreting P-NEN [35]. 
This may be associated with diagnostic difficulties be-
cause few laboratories can provide a reliable assessment 
of CCK concentration.
Biochemical diagnostics of type 3 g-NENs:
 — determination of serum CgA concentration is recom-
mended (*evidence level 5);
 — level of neuron-specific enolase (NSE) is higher in 
poorly differentiated neoplasms than in NETs, and 
it significantly correlates with the length of survival 
(*evidence level 5);
 — determination of CgA (and daily urinary excretion of 
5-HIAA in the case of atypical carcinoid syndrome, 
or serum ACTH and cortisol if ACTH-secreting tu-
mour is suspected) (*evidence level 5).
3.1.2. Neuroendocrine neoplasms of the duodenum
 — determination of CgA (*evidence level 5),
 — gastrin in patients with ZES, in justified cases the 
test with secretin [33], (*evidence level 3),
 — if clinical symptoms suggestive of ectopic hormone 
production by duodenal NEN occur, the following 
hormones should be determined (regardless of clini-
cal symptom characteristics): adrenocorticotropic 
hormone (ACTH) and cortisol, insulin, and peptide 
C, as well as glucagon, insulin-like growth factor 1 
(IGF 1) and growth hormone (GH), also in functional 
tests [33], (*evidence level 5);
 — in patients with: duodenal NEN and clinical charac-
teristics of MEN-1 syndrome, positive family history 
of MEN-1, and multi-focal duodenal NEN genetic 
tests for the presence of germinal menin gene muta-
tion should be performed. Examination of somatic 
mutation in the tumour is not recommended [12] 
(*evidence level 4).
Minimal consensus statement on biochemical exa-
minations:
CgA — regardless of clinical symptoms (*evidence 
level 5);
Gastrin — in ZES (*evidence level 3);
5-HIAA — in typical and atypical carcinoid syndrome 
(*evidence level 3).
ACTH and cortisol (in a test with 1 mg of dexametha-
sone) if ACTH secretion by the tumour is suspected (*evi-
dence level 3).
3.2. Pathomorphological diagnostics
3.2.1. Pathogenesis
Gastric NENs are usually non-functional tumours 
arising from enterochromaffin-like (ECL) cells produc-
ing histamine, and are most frequently found in the 
*evidence level according to OCEMB [87]
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fundus and body of the stomach. Less common are 
gastrin-producing G cells, present in large quantities 
in the pylorus, somatostatin-producing D cells, dif-
fused in small quantities throughout the stomach, and 
serotonin-producing ECL cells, very rarely found in 
the stomach [8,9]. Gastric NENs are divided into three 
types, according to their clinical and morphological 
characteristics, following the AJCC Cancer Staging 
(Eighth Edition 2017) [36] and UICC (Eighth Edition 
2017) [37]. Table I presents the characteristics of each 
group of neoplasms.
Type 1 gastric NENs occur most frequently. They 
develop in the gastric mucosa in the course of atrophic 
gastritis with concomitant hypergastrinaemia in the 
form of multiple polyps and nodules in the body of the 
stomach. The precursor is a linear or nodular hyperplasia 
of the ECL cells, associated with an increased risk of 
ECLoma [6]. Type 1 tumours are usually benign and can 
disappear after resection of the prepyloric part, although 
currently this approach is not recommended [38].
In the case of multiple gastric polyps, pathomorpho-
logical diagnosis requires differentiation of ECLoma 
from other lesions, such as hyperplastic or inflammatory 
polyps, adenomas, or early carcinoma type 0-I. A biopsy 
of different lesions is recommended, particularly of 
those that differ in macroscopic appearance, and from 
the fundus and body of the stomach, in order to verify 
atrophic inflammation [6].
Type 2 gastric NENs are rare. The tumours are usu-
ally more than 2 cm in diameter, invading the muscula-
ris propria and demonstrating angioinvasive properties. 
Germinal mutation tests are recommended in patients 
with suspected MEN-1 in cases with ECLoma and 
Zollinger-Ellison Syndrome, or with a family history 
suggestive of MEN-1 or multiple tumours without 
evidence of atrophic gastritis. Examination of somatic 
mutations in gastric NETs is not recommended [12].
Gastric NETs of type 1 and 2 are usually well-differen-
tiated neuroendocrine neoplasms (NET G1 or NET G2).
Type 3 is the second most common gastric neu-
roendocrine neoplasm. It is a sporadic tumour, not 
associated with atrophic inflammation or hyperplasia 
of the neuroendocrine cells. Neoplasms of more than 
2 cm in diameter, angioinvasion, and infiltration of the 
muscularis propria are the risk factors for metastases. 
This neoplasm is characterised by unfavourable prog-
nosis, fast progression, and an aggressive course [6, 7].
3.2.2. Diagnostic algorithm
Diagnosis of gastric NENs is based on the histopatho-
logical examination of the polyps after their endoscopic 
resection in the case of NENs of type 1 and 2 (NET G1 
and NET G2), or the surgical material obtained after 
resection of the stomach and lymph nodes in gastric 
NENs of type 3 (NETs G3 and NECs) [11, 36, 37].
A. Microscopic assessment of type 1 gastric NETs:
A type 1 gastric NET is a well-differentiated neu-
roendocrine neoplasm with the macroscopic appear-
ance of a polyp[s]. In such cases, NETs G1 are usually 
diagnosed, and only sporadically NETs G2 [6].
In the microscopic assessment, the following para-
meters need to be determined:
 — type of neoplasm according to the WHO 2017 clas-
sification [11];
 — differentiation grade G on the basis of the Ki-67/MIB1 
proliferation index and the number of mitotic figures;
 — polyp resection margin;
 — and angioinvasion properties.
B. Macroscopic assessment of the surgical material 
includes the following parameters [39]:
The dimensions of the gastric fragment obtained 
for examination, with the description of the tumour 
location relative to the resection margins.
Tumour size (if possible, in three dimensions). Con-
dition of the mucosa at the tumour site (ulcerated/non- 
-ulcerated). Tumour position relative to the stomach 
wall layers; tumour cross-sectional image, taking into 
consideration the areas of necrosis and extravasations.
Number and size of the lymph nodes.
Image of the mucosa in the remaining part of the slide 
(all changes need to be examined histopathologically).
Presence of other lesions in the gastric wall.
Width of surgical margins.
Table I. Types of gastric neuroendocrine neoplasms  [6, 36, 37]
Type 1 Type 2 Type 3
Frequency 70–80% Rare 10–15%
Tumour 0.5–1.0 cm Usually up to 
1.5 cm
Varied, mostly 
> 2 cm
Number of 
tumours
Multiple, small 
nodules, polyps
Multiple Single
Site Body Body Entire stomach
Associated 
conditions
Hypergastrinaemia
Chronic atrophic 
gastritis
ECL hyperplasia
MEN type 1, 
hypergastrinaemia
Zollinger-Ellison 
Syndrome
Sporadic
Clinical 
course
Usually mild, 
limited to mucosa, 
submucosa
30% metastases 71% of tumours 
> 2 cm 
Invasion of 
muscularis 
propria, vessels, 
lymph nodes
Demo-
graphic 
character-
istics
70–80% females 
50–60 years of 
age
Females = 
Males, 
mean age  
50 years
Males more 
frequently, 
mean age  
55 years
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C. Microscopic assessment of the surgical material is 
based on assessment of the following parameters:
Histological type of the NEN according to the 
WHO 2017 classification [11], including division into 
NET G1 and NET G2, completed in rare cases with 
well-differentiated tumours of NET G3, according to 
the Eighth Edition AJCC Cancer Staging 2017 [36] and 
UICC 8 2017 [37]. Highly malignant NECs and mixed 
neoplasms are classified according to the criteria for 
classical adenocarcinomas.
The histological grade G according to ENETS 2016/ 
/WHO 2017, including the assessment of the number 
of mitotic figures in 1-HPF and proliferation index 
Ki-67, expressed as the percentage of tumour cells with 
immunohistochemical expression of MIB1 per 500 to 
2000 tumour cells in a hot spot.
Pathomorphological pTNM staging according to 
AJCC/UICC (Table II).
Assessment of surgical margins.
Lesions in the gastric mucosa other than a tumour:
 — presence/absence of atrophic inflammation,
 — hyperplasia of ECL cells,
 — other lesions.
Assessment of immunohistochemical expression of 
neuroendocrine markers: CgA and synaptophysin, as 
well the Ki-67/MIB1 proliferative activity (obligatory).
Immunohistochemical assessment of the markers: 
NSE, CD56, CDX2, and serotonin (conditional).
Histopathological types of the NENs according to 
the WHO 2017 classification and the histological grade 
(G) according to the ENETS 2016/WHO 2017 criteria are 
presented in “Diagnostic and therapeutic guidelines for 
gastro-entero-pancreatic neuroendocrine neoplasms” 
(see p. 79–110).
3.2.3. Neuroendocrine neoplasms of the duodenum
According to the WHO 2017 classification [11], duodenal 
neuroendocrine neoplasms are usually well-differen-
tiated NETs G1 (50–75% of cases), less often NETs G2 
(25–50% of cases), and are only sporadically poorly differ-
entiated neuroendocrine carcinomas (up to 3% of cases).
Grading of neuroendocrine neoplasms is conducted 
on the basis of mitotic activity (per ten high-power fields) 
and proliferation activity measured using the Ki-67 index.
Diagnostic algorithm
A histopathological report from the assessment of the sur-
gical material — duodenal neuroendocrine neoplasms:
A. Macroscopic description [39]:
Dimensions of the duodenum fragment obtained 
for examination, with the description of the tumour 
location relative to the resection margins and adjacent 
tissues.
Tumour size (if possible, in three dimensions). 
Condition of the mucosa at the tumour site (ulce-
rated/non-ulcerated). Tumour position relative to the 
duodenum wall layers and adjacent tissues; tumour 
cross-sectional image, taking into consideration the 
areas of necrosis and extravasations.
Number and size of the lymph nodes.
Image of the mucosa in the remaining part of the slide 
(all changes need to be examined histopathologically).
Presence of other lesions in the duodenal wall.
B. Microscopic description:
Histopathological diagnosis (considering all the 
properties mentioned in the classification):
 — histological type according to the WHO 2017 clas-
sification [11] and criteria presented in the Eighth 
Edition AJCC Cancer Staging 2017 [36] and Eighth 
Edition UICC [37];
 — histological grading (G) according to ENETS 2016/ 
/WHO 2017 and criteria of the Eighth Edition AJCC 
Cancer Staging 2017 and Eighth Edition UICC; (see 
“Diagnostic and therapeutic guidelines for gastro-
entero-pancreatic neuroendocrine neoplasms 
(recommended by the Polish Network of Neuroen-
docrine Tumours)” (p. 79).
 — pTNM pathomorphological staging according to the 
Eighth Edition AJCC Cancer Staging 2017 [36] and 
Eighth Edition UICC [37].
presence/absence of angioinvasion characteristics.
Tumour position relative to the anatomical layers 
of the duodenal wall and adjacent tissue (depth of the 
invasion).
Table II. Classification pTNM of gastric and duodenal 
neuroendocrine tumours according to UICC/AJCC, 2017 [36, 
37]
Primary 
tumour 
feature
pT
Comments
TX Primary tumour was not assessed
T0 No tumour structure 
T1 Invasion of the lamina propria of the mucosa or 
submucosa by the tumour, neoplasm, tumour size ≤ 1 cm
T2 Invasion of muscularis propria or tumour size > 1 cm
T3 Invasion of muscularis propria and subserosa, without 
invasion of serosa
T4 Invasion of serosa or other organs or adjacent 
structures
*evidence level according to OCEMB [87]
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Width of surgical margins.
Lesions in the duodenal mucosa other than the 
tumour.
Obligatory immunohistochemical examinations: 
CgA, synaptophysin, and Ki-67/MIB1.
Conditionally — assessment of the neuroendocrine 
properties of the neoplasm in the immunohistochemi-
cal examination (intensity and steadiness of reaction 
should be reported, and possibly the manufacturer of 
the reagents used should be mentioned; in patients with 
MEN-1 syndrome and gastrinoma located in the duode-
num, immunohistochemical assessment of gastrin and 
other hormone expression, both in the primary tumour 
and in the metastatic foci, should be performed):
 — gastrin, serotonin, and SSA (additionally PP, calci-
tonin, insulin, glucagon);
 — S-100, NSE (in the case of gangliocytic paragan-
glioma).
Fine-needle aspiration biopsy may be useful in the 
assessment of the stage of clinical advancement of the 
disease (diagnosis of neoplastic metastases in the lymph 
nodes and liver). Cytological smears can also be used 
for immunocytochemical examinations.
TNM classification of duodenal neuroendocrine 
tumours (Tables II and III) [36, 37].
T — primary tumour;
TX — primary tumour cannot be evaluated;
T1 — tumour invades lamina propria or submucosa 
and is ≤ 1 cm in diameter (duodenal neoplasm);
T2 — tumour invades muscularis propria or is 
> 1 cm (duodenal neoplasms);
Neoplasm invades through the sphincter sub-
mucosal membrane or muscularis propria, or is 
> 1 cm in diameter (neoplasms of the ampulla).
T3 — tumour invades the pancreas or peripancreatic 
fat tissue;
T4 — neoplasm invades the peritoneum or other 
organs
(for each T add “m” in multiple lesions).
N — regional lymph nodes
NX — regional lymph nodes cannot be assessed;
N0 — no metastases in the regional lymph nodes;
N1 — presence of lymph node metastases.
M — distant metastases
MX — distant metastases cannot be assessed;
M0 — no distant metastases;
M1 — distant metastases;
M1a — only hepatic metastases;
M1b — metastases to at least one extrahepatic loca-
tion (e.g. lungs, ovaries, extra-regional lymph nodes, 
peritoneum, bones);
M1c — hepatic and extrahepatic metastases;
Clinical advancement staging is presented in Table III.
Minimal consensus statement on pathomorphological 
examination:
Minimal histopathological report for gastroduodenal NEN 
should include:
 — histological type of the neoplasm according to the WHO clas-
sification, considering the division into well-differentiated 
neuroendocrine neoplasms (NET G1, NET G2, and NET 
G3) and neuroendocrine carcinomas (NECs) or mixed neu-
roendocrine-non-neuroendocrine neoplasm (MiNEN); (see 
“Diagnostic and therapeutic guidelines for gastro-entero-
pancreatic neuroendocrine neoplasms (recommended by the 
Polish Network of Neuroendocrine Tumours)” (p. 79–110);
 — histological G grading referring to well-differentiated 
neoplasms (NET G1, NET G2, NET G3);
 — assessment of polyp resection or surgical margins in the 
surgical material;
 — pTNM histopathological staging according to ENETS and 
AJCC or UICC classifications (it is important to provide 
the affiliation of the classification in each case).
 — The histopathological diagnosis of the NEN must be 
confirmed by immunohistochemical tests assessing expres-
sion of the neuroendocrine markers: synaptophysin and 
chromogranin A, as well as Ki-67 proliferative activity 
using the MIB1 antigen (*evidence level 3).
3.3. Location diagnostics of gastroduodenal 
neuroendocrine neoplasms
3.3.1. Neuroendocrine neoplasms of the stomach
Gastric neuroendocrine tumour type 1:
Gastric neuroendocrine neoplasms of type 1 usually 
occur as multiple, small polyps of < 1–2 cm in patients 
with atrophic gastritis. The basic examination in imaging 
diagnostics is endoscopy of the upper gastrointestinal tract 
with a biopsy and/or complete removal of the largest tu-
mour for histopathological examination. Also, two samples 
from the antrum need to be obtained for histopathological 
examination, as well as four samples from the fundus/
body of the stomach [6, 40, 41]. It is also recommended 
to obtain a biopsy from the antrum and from the body 
of the stomach for a quick urease test if Helicobacter pylori 
infection was not assessed with the use of other methods.
Table III. Disease staging for gastric and duodenal neuroendocrine 
tumours [36,37]
Stage T feature N feature M feature
I T1 N0 M0
IIa T2 N0 M0
IIb T3 N0 M0
IIIa T4 N0 M0
III Any T N1 M0
IV Any T Any N M1
*evidence level according to OCEMB [87]
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In the case of tumours > 1–2 cm and/or multiple 
tumours, endoscopic ultrasonography should be per-
formed before deciding on endoscopic treatment, to 
assess the depth of the intramural invasion [10, 42].
In selected cases, to assess the disease staging, 
three-phase CT (computed tomography) examination 
with water-filling of the stomach and after IV contrast 
administration should be performed as an initial (base-
line) examination, and usually every six months, or 
depending on the clinical symptoms, as a surveillance 
examination during the clinical follow-up [43].
Gastric neuroendocrine tumours type 2:
Similarly to type 1 lesions, type 2 gastric neuroendocrine 
tumours are usually small (< 1–2 cm), often multiple 
polyps, typically located in the fundus and body of the 
stomach. As they develop in the course of gastrinoma, 
they may be associated with other changes, such as 
severe reflux oesophagitis or thickening of the gastric 
folds. The basic diagnostic tests include endoscopy of 
the upper gastrointestinal tract with a biopsy and/or 
complete removal of a small tumour for histopatho-
logical examination; also, in the case of larger and/or 
multiple tumours, two samples from the antrum need 
to be obtained for histopathological examination, as well 
as four samples from the fundus/body of the stomach, 
and tests should be performed to determine the H. pylori 
infection [6].
In the case of tumours > 1–2 cm and/or multiple 
tumours, EUS should be performed in order to assess 
the depth of the intramural invasion [10, 42].
As in the case of type 1 lesions, to exclude the 
presence of metastases, a three-phase computed to-
mography examination should be further considered 
as an initial (baseline) examination, and then every 
six months, or depending on the clinical symptoms, 
as a surveillance examination during clinical follow-
-up [43].
A radioisotope somatostatin receptor imaging (SRI) 
test should be performed in well-differentiated lesions 
to determine the disease staging during clinical follow-
-up, usually every 9–12 months, or depending on the 
clinical symptoms, and if discrepancies between the 
clinical, biochemical and structural examination results 
occur. This test is necessary before introducing therapy 
with somatostatin analogues (PRRT) [6].
Gastric neuroendocrine tumours type 3 (sporadic):
These are single, ulcerated, large lesions > 2 cm in dia-
meter, usually located in the fundus and body of the 
stomach. Endoscopy of the upper gastrointestinal tract 
should be performed, and tumour samples obtained 
for diagnosis.
EUS can be used to assess the depth of intramural 
invasion, and the presence of metastases to the regional 
lymph nodes [6].
Abdominal ultrasonography (USG) enables identifi-
cation of hepatic and lymph node metastases, provid-
ing the optimal conditions for the examination of the 
abdominal cavity or superficial lymph nodes, as well as 
other tissues involved in the neoplastic process.
Three-phase CT examination with water-filling of the 
stomach and after IV contrast administration according 
to the protocol, as in the case of gastric neuroendocrine 
neoplasms of type 1, should be performed each time, 
to assess the staging as an initial (baseline) examina-
tion, and during the clinical follow-up, as a surveillance 
test, usually every 3–6 months, or depending on the 
histopathological diagnosis, baseline staging, and the 
conducted active antineoplastic treatment in the case 
of advanced disease, non-resectable neoplasms, with or 
without progression, as well as according to the concur-
rent symptoms of local advancement or clinical and bio-
chemical symptoms, such as carcinoid syndrome [43, 44].
If a CT scan cannot be performed (allergy to iodine 
agents is not an absolute contraindication for the test, 
which may be performed after proper antiallergenic 
premedication), magnetic resonance imaging (MRI) of 
the abdominal cavity before and after IV contrast ad-
ministration should be performed. Particularly useful 
for the assessment of hepatic metastases are sequences 
DWI and 3D, T1 before and after contrast administra-
tion — a dynamic examination, e.g. LAVA/VIBE [44, 45].
Magnetic resonance of the spine or bone scintigra-
phy should be performed if any osseous metastases are 
clinically suspected or visible on the CT scan.
If bone metastases are present, accompanied by cli-
nical symptoms (pain), palliative radioisotope therapy 
of bone pain should be considered (89Sr, 153Sm), follow-
ing a positive verification in a 99mTcMDP scintigraphic 
examination [46] (*evidence level 3).
3.3.2. Neuroendocrine neoplasms of the duodenum:
A sensitive method for detecting duodenal neuroendo-
crine tumours is endoscopy of the upper gastrointes-
tinal tract, conducted with the use of straight/curved 
probes with biopsy and/or complete removal of the 
tumour for histopathological examination. In the case 
of hormonally functional tumours with characteristics 
of gastrinoma, upper gastrointestinal endoscopy may 
demonstrate specific lesions associated with gastric 
hypersecretion, such as multiple gastric and duodenal 
ulcers, and even small intestinal ulcers, or severe reflux 
oesophagitis (Zollinger-Ellison syndrome) [6,47].
EUS with an optional fine-needle aspiration biopsy 
should be performed in the case of larger tumours, to 
*evidence level according to OCEMB [87]
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assess the extent of the intramural invasion, and in any 
non-diagnostic endoscopy [48,49,50,51].
To assess the disease staging, the following examina-
tions need to be further performed:
 — three-phase computed tomography after oral ad-
ministration of water in two stages — 500 mL half 
an hour before the test, and, optimally, 500 mL 
immediately before the test, if possible, depend-
ing on the patient’s clinical condition, for optimal 
expansion of the gastroduodenal lumen, and after 
IV contrast administration [44].
The test should be performed in order to deter-
mine the disease staging, as an initial (baseline) exa-
mination, and, depending on the disease stage, as 
a surveillance examination during active combined 
treatment, to assess the effectiveness in the case of 
advanced lesions.
 — an SRI test should be performed in advanced 
lesions, to determine the disease staging during 
follow-up, usually every 9–12 months, or depend-
ing on the clinical symptoms, and if discrepancies 
between clinical, biochemical, and structural 
examination results occur. This test is necessary 
before introducing therapy with somatostatin 
analogues/PRRT [6] — if duodenal neuroendo-
crine tumours are not visible in the structural 
and functional examinations, and in the case of 
a functional tumour, intraoperative USG is the 
examination of choice;
 — magnetic resonance of the spine or bone scintigraphy 
should be performed if any osseous metastases are 
clinically suspected or visible on the CT scan, in order 
to assess the staging. If bone metastases are present, 
accompanied by clinical symptoms (pain), palliative 
radioisotope therapy of bone pain should be consid-
ered, following a positive verification in a 99mTc-MDP 
scintigraphic examination [46] (*evidence level 3).
Minimal consensus statement on location examina-
tions:
 — Upper gastrointestinal endoscopy with a histopathological 
examination of the obtained material and endoscopic ultra-
sonography are the methods of choice in the diagnostics of 
most gastroduodenal neuroendocrine tumours.
 — Computed tomography of the abdominal cavity following 
contrast IV, magnetic resonance, and receptor scintigraphy 
imaging should be used to assess the disease staging and 
detect potential distant metastases.
 — In patients with advanced disease (e.g. with hepatic 
metastases), structural examinations (endoscopy, EUS, 
CT, and MRI) should be performed, and in NET, radio-
isotope somatostatin receptor imaging (SRI) should be 
conducted, to establish the optimal future treatment 
(*evidence level 3).
4. Treatment
4. 1. Endoscopic and surgical treatment  
of gastroduodenal neuroendocrine tumours
4.1.1. Gastric neuroendocrine tumours (type 1–3)
In well-differentiated neoplasms less than 1 cm, only 
observation and control endoscopy every 12 months is 
possible [52], or endoscopic excision [10].
In well-differentiated neoplasms larger than 
1 cm, in EUS test not invading the muscularis propria, 
endoscopic mucosal dissection (ESD) is the preferred 
method [53].
After endoscopic treatment it is recommended 
that a surveillance examination is conducted every 
12 months [54, 55, 56]
In type 3 neoplasms, with the exception of small le-
sions that can be removed with ESD [57], the preferred 
method, as in other types deeply invading the organ 
wall, is surgical procedure.
4.1.2. Neuroendocrine neoplasms of the duodenum
In tumours of ≤ 1 cm, not invading the muscularis propria 
in the EUS examination, after exclusion of metastases, if it 
is possible from the technical point of view, and there is 
access to a centre with suitable experience, they may be 
removed via endoscopic submucosal dissection [6, 58, 59].
If ESD cannot be performed, consideration of local 
surgical removal is recommended.
Tumours larger than 2 cm and any tumour with 
lymph node metastases, regardless of its size, should 
be managed radically by surgical treatment.
Tumours of 1–2 cm:
 — without lymph node invasion: local excision;
 — with invasion of lymph nodes: radical surgical 
procedure.
 — neoplasms with hepatic metastases: if surgical 
excision or local ablation of metastases is
 — possible, a radical surgical procedure within the 
duodenum should be performed [60, 61].
4.1.3. Gastrinoma
Sporadic gastrinoma:
 — if the disease is not generalised, distal pancreatec-
tomy should be performed, if the tumour is located 
in the peripheral part of the pancreas;
 — with the tumour located in the pancreatic head — 
if it is possible from the technical point of view, an 
attempt should be made to enucleate the tumour; 
if this is not possible, a pancreatoduodenectomy 
should be performed;
 — with the tumour located in the duodenal wall it is 
necessary to perform duodenectomy with tumour 
excision or pancreatoduodenectomy.
*evidence level according to OCEMB [87]
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Gastrinoma in MEN-1 (most frequently multiple) — 
radical treatment is rarely possible. If the disease seems 
to be limited, an attempt to perform a radical resection 
can be made [39].
Minimal consensus statement on endoscopic/surgical 
treatment: 
In gastric NENs of type 1, larger than 1 cm, without inva-
sion of muscularis propria, endoscopic submucosal dissection 
is the treatment of choice. Smaller tumours may be observed.
In gastric NENs of type 3, as in other types of neoplasm 
deeply invading the organ wall, surgical procedure is the 
treatment of choice.
In duodenal NENs of ≤ 1 cm, without invasion of muscu-
laris propria, after exclusion of metastases, endoscopic submu-
cosal dissection is the treatment of choice. Tumours larger than 
2 cm, and any tumour invading the muscularis propria or/ 
/and with lymph node metastases, should be surgically treated.
In the case of gastrinoma, surgical removal of the primary 
tumour(s) should be the target (*evidence level 3).
4.2. Pharmacological treatment
4.2.2. Neuroendocrine neoplasms of the stomach
Gastric neuroendocrine tumours of type 1
Typically, patients with gastric NENs of type 1 do not 
require pharmacological treatment [32]. Sometimes 
individual attempts are made to introduce treatment 
with somatostatin analogues (SSA) because they 
inhibit hypergastrinaemia, prevent hyperplasia of 
the ECL cells, and result in tumour regression [6]. It 
should be emphasised that the effect of SSA has not 
been compared to the surveillance strategies; there-
fore, SSA treatment cannot be recommended in early 
disease stages. SSA may be useful in the treatment 
of patients with multiple, small lesions, which are 
difficult to remove endoscopically [62]. This therapy 
may be the right option for patients with metastatic 
disease and proven SSTR2 expression, as well as low 
Ki-67 value. Studies without control groups revealed 
that netazepid, an antagonist of the gastrin/chole-
cystokinin receptor, demonstrates antiproliferative 
properties in g-NEN [63, 64]. However, it cannot be 
universally recommended, and further assessment 
of this therapy in controlled randomised studies is 
necessary (*evidence level 5).
Gastric neuroendocrine tumours of type 2
Zollinger-Ellison Syndrome (ZES)
The aims of ZES therapy are: 1) to normalise secre-
tion of hydrochloric acid, 2) to manage gastrinoma, and 
3) to treat gastric type 2 NET (which develops in 13–30% 
of patients with ZES/MEN-1) [12].
Excessive secretion of gastric acid in gastrinoma 
must be inhibited pharmacologically in all patients with 
gastrinoma, in order to prevent complications.
The treatment of choice involves PPI (*evidence level 
3). All marketed PPI (omeprazole, lansoprazole, pan-
toprazole, rabeprazole, esomeprazole) reveal similar 
effectiveness. Administration of PPI once or twice a day 
is effective in most patients. According to the available 
guidelines [23, 30], PPI used in high doses (3–4 times 
the standard dose) are the medications of choice. The 
recommended initial dose for omeprazole in sporadic 
forms of ZES is 60 mg once a day, for pantoprazole 
— 80 mg once a day, for rabeprazole — 60 mg once 
a day, and for esomeprazole — 2 × 40 mg. In patients 
with ZES complications (MEN-1 with hypercalcaemia, 
severe GERD symptoms, preceding Billroth II resec-
tion), higher doses of anti-secretive medications are 
used (daily dose for omeprazole is up to 120 mg, for 
pantoprazole — 160 mg, and for rabeprazole — up to 
120 mg, for esomeprazole — up to 160 mg — each of 
them in two divided doses) [7]. In individual cases, 
PPI therapy may begin with intravenous administra-
tion (e.g. pantoprazole 80 mg every eight hours [65]). 
Intravenous administration is also recommended if 
medications cannot be taken orally. Good control of 
symptoms caused by excessive production of hydro-
chloric acid achieved with PPI therapy enables surgical 
intervention [66]. If surgical treatment is not possible, 
PPI therapy should be continued for an indeterminate 
period of time. It should be emphasised that in patients 
after a successful gastrinoma resection, use of PPI may 
still be necessary because in most of these patients, 
despite the surgery, hypersecretion is observed [67]. 
Discontinuation of PPI and resulting rebound hyper-
secretion may result in severe complications, such as 
perforation or gastrointestinal stenosis [68]. However, 
in some patients PPI doses may be reduced during the 
follow-up [64].
The effectiveness and favourable safety profile of 
long-term therapy with high doses of PPI has been 
confirmed by studies [69].
The most recent studies [70–72] do not confirm 
previous reports regarding the effect of long-term PPI 
therapy on vitamins B12 and D3 concentrations. How-
ever, there have been reports suggesting an increased 
risk of Clostridium difficile infection and community-
acquired pneumonia in patients using PPI.
Histamine H2-receptor antagonists may also be used 
in patients with ZES. It should be noted that the time 
of action of H2-receptor inhibitors is shorter compared 
to PPI, and tachyphylaxis is observed, which makes 
them second-line medications. Patients with gastrinoma 
*evidence level according to OCEMB [87]
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require higher and more frequent doses of H2 blockers 
than patients with idiopathic peptic ulcer disease. High 
doses of histamine H2-receptor antagonists can also be 
administered by constant intravenous infusion.
Long-acting somatostatin analogues are not first-
line medications, and they should be used only in the 
case of a PPI treatment-resistant, malignant gastrinoma 
(*evidence level 3). Presently, studies on the effective-
ness of treatment of g-NET type patients with gastrin/ 
/cholecystokinin receptor antagonist (netazepid) are 
being conducted.
In MEN1 syndrome, surgical resection of the para-
thyroids in primary hyperparathyroidism reduces ex-
cessive secretion of hydrochloric acid [30].
In the view of the RADIANT-4 study results, in 
patients with advanced non-functional NET G1/G2, 
after progression is observed, within six months the 
recommended treatment is everolimus (presently non- 
-refundable in Poland) [73].
Gastric neuroendocrine tumours of type 3
Systemic treatment may be used in patients with 
inoperable lesions or in generalised stage (CS IV) [6].
Neuroendocrine carcinoma (NEC)
In patients diagnosed with NEC, the principles of 
local and systemic treatment are the same as in patients 
with adenocarcinoma. The systemic treatment of choice 
is chemotherapy (recommendations presented in the 
section on general guidelines). Cytostatics such as: 
5-fluorouracil, capecitabine, dacarbazine, oxaliplatin, 
streptozocin, or temozolomide may be considered in 
patients with progressing disease in metastatic NENs 
and NECs, if there are no other therapeutic options [74] 
(*evidence level 3).
There are no studies on the role of perioperative 
chemotherapy in patients with locally advanced 
gastric NEC. After radical surgical treatment of NEC 
with high proliferation index (Ki 67 > 55%), adjuvant 
chemotherapy using platin derivatives combined with 
etoposide is recommended [75].
In patients with non-resectable, locally advanced, or 
generalised disease, chemotherapy is the treatment of 
choice, provided the patient is in good condition and 
liver, kidney, and bone function is satisfactory (a de-
tailed description of this form of treatment is presented 
in general guidelines on the management of GEP NEN, 
see p. 79–110).
4.2.3. Neuroendocrine neoplasms of the duodenum
Treatment of gastrinoma should be analogous to that 
of gastric NETs of type 2, whereas other tumours, es-
pecially disseminated ones associated with carcinoid 
syndrome, should be treated like gastric tumours at the 
same stage of advancement.
Chemotherapy in the treatment of poorly differen-
tiated duodenal neuroendocrine neoplasms is similar 
to that used for the therapy of small-cell carcinoma.
Minimal consensus on pharmacotherapy:
1. Stomach:
Type 1 — eradication of H. pylori (*evidence level 3).
Type 2 — eradication of H. pylori, PPI (*evidence level 3).
With somatostatin analogues to be considered in the case 
of: malignant gastrinoma, multiple, small g-NETs of type 1 
(difficult to remove endoscopically), metastatic disease with 
confirmed SSTR2 expression, and low Ki-67 value (*evidence 
level 5).
Type 3
Chemotherapy in patients with a locally advanced non-re-
sectable disease and/or generalised disease (*evidence level 3).
2. Duodenum:
ZES — PPI, H2 blockers (*evidence level 3).
ZES/MEN1 — PPI, treatment of hypercalcaemia (*evi-
dence level 3).
Hormonally non-functional neoplasms — symptomatic 
treatment (*evidence level 4).
Functional neoplasms — treatment specific for the type of 
hormonal activity, somatostatin analogues (*evidence level 3).
4.3. Radioisotope therapy
4.3.1. Gastroduodenal neuroendocrine tumours
Isotope therapy with labelled somatostatin analogues 
(Peptide Receptor Radionuclide Therapy — PRRT) is 
a form of palliative treatment rarely used in gastric NENs 
[46, 76, 77]. Eligibility for the treatment is in accordance 
with the principles presented in the general section.
In NETs of type 1 or type 2 there are no data re-
garding radioisotope treatment. Apart from surgical 
treatment, chemotherapy is the basic treatment for 
gastric neuroendocrine tumours of type 3, in the case of 
disseminated disease [78]. Information on the possible 
use of PRRT treatment in gastric NETs of type 3 is very 
limited, the literature data present only individual cases. 
Both in gastric NETs of type 3 and duodenal NETs, PRRT 
may be used in advanced, non-resectable, progressive 
processed cases, after the failure of previous treatment 
[79–81]. This treatment may be conducted in the case of 
the confirmed high expression of somatostatin recep-
tors (SSTR) on the tumour cells in an SRI examination, 
and when there are no contraindications for this type 
of therapy [79-84]. Early radioisotope diagnostics allow 
the determination of the advancement of the neoplastic 
process, and eligibility for the treatment with radio-
isotope-labelled somatostatin analogues. After PRRT, 
somatostatin receptor imaging enables assessment of 
treatment effectiveness [85].
In NETs associated with the clinical symptoms of 
functional tumour, such as carcinoid syndrome (stom-
*evidence level according OCEMB [87]
151
Endokrynologia Polska 2017; 68 (2)
SZ
K
O
LE
N
IE
 
PO
D
YP
LO
M
O
W
E
ach) and Zollinger-Ellison Syndrome (ZES, stomach, 
and duodenum), where exacerbation of the symptoms 
or lack of symptom control with other forms of treat-
ment is observed, PRRT should be considered earlier, 
often in combination with symptomatic treatment using 
“cold” somatostatin analogues [86]. In advanced gas-
troduodenal NET G3, PRRT may be considered when 
other treatment methods have been exhausted, and 
a high somatostatin receptor expression is maintained in 
the SRI examination. The literature data on this subject 
are limited to individual cases [46, 77, 79, 80–81].
Summary
PRRT in gastric NETs is rarely used. Information on this 
subject is very limited. It may be considered in type 3 
gastric NETs G1 and G2, temporarily in NETs G3, in 
advanced, non-resectable, and progressive process, if 
previous therapy is ineffective and/or not tolerated, 
provided a high expression of receptors is confirmed 
in the SRI examination (*evidence level 4).
In duodenal NETs, PRRT may be considered in an 
advanced, non-resectable, and progressive process, if 
the previous therapy is ineffective and/or not tolerated, 
provided a high expression of receptors is confirmed in 
the SRI examination. Similarly, in duodenal NETs G3, 
PRRT may be considered if the conditions presented 
above are met (*evidence level 4).
Minimal consensus statement on radioisotope treat-
ment:
The basic form of therapy in gastroduodenal NETs is 
endoscopic or surgical treatment, in the case of large lesions 
and an inability to provide endoscopic treatment.
In gastroduodenal NETs G1 and G2, PRRT may be con-
sidered in advanced, non-resectable, and progressive processes, 
if the previous therapy proves ineffective, and a high SSTR 
expression is confirmed in the SRI examination.
In NETs G3 of the stomach and duodenum, PRRT is 
considered individually, in the case of advanced, progressive 
disease, if other therapeutic options have been ineffective, 
and a high SSTR expression has been confirmed in the SRI 
examination (*evidence level 4).
5. Follow-up
Minimal consensus statement on follow-up [39]:
Biochemical tests:
Stomach:
type 1 and type 2: 
 —  1–3 years — anamnesis and physical examination every 
6–12 months; 
 —  4–10 years — anamnesis and physical examination every 
12 months (*evidence level 3);
type 3:
 — first year: anamnesis and physical examination every 
3–12 months (*evidence level 3), CgA every 3-12 months 
(*evidence level 5);
 — 2-10 years: anamnesis and physical examination every 
12 months (*evidence level 3), CgA every 12 months 
(*evidence level 5).
Duodenum:
 — first year: every 3–12 months anamnesis and physical 
examination, CgA (*evidence level 5);
 — 2-10 years: every 6–12 months anamnesis and physi-
cal examination (*evidence level 3), CgA (*evidence 
level 5).
Gastrinoma:
 — first year: every 3–12 months anamnesis and physical 
examination (evidence level 3), gastrin (*evidence level 
3), CgA (*evidence level 5); 
 — 2–10 years: every 6–12 months anamnesis and physical 
examination (*evidence level 3), gastrin (*evidence level 
3), CgA (*evidence level 5);
Imaging examinations
Stomach:
 — type 1 and type 2: upper gastrointestinal endoscopy 
every 6–12 months, other imaging examinations (CT, 
MRI) depending on the stage of the disease;
 — type 3: upper gastrointestinal endoscopy every 3–6 
months, other imaging examinations (CT, MRI) every 
3–6 months.
Duodenum:
NET — upper gastrointestinal endoscopy every 6–12 
months, other imaging examinations (CT, MRI), depending 
on the stage of the disease, every 6–12 months;
NEC — upper gastrointestinal endoscopy every 3–6 
months, other imaging examinations (CT, MRI) every 3–6 
months.
In individual cases for patients with previously confirmed 
somatostatin receptor expression, an SRI examination should 
be included in the monitoring of NET.
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